How much funding has Invivyd raised?

Invivyd has raised $466.0M in total funding, most recently a Series C round.

Who are Invivyd's investors?

Invivyd's investors include RA Capital Management, Polaris Partners, Mithril Capital, Janus Henderson Investors, GV (Google Ventures), Redmile Group.

Where is Invivyd headquartered?

Invivyd is headquartered in Waltham, Massachusetts, United States.

What industry is Invivyd in?

Invivyd operates in Biotech, Healthcare.

Invivyd

IPO

Antibody-based therapies to address evolving viral threats

Public · Waltham, United States · Founded 2020 · $466.0M raised

Biotech

Healthcare

Headquarters: Waltham, Massachusetts
Employees: 51–200
Founded: 2020
Business Model: B2B
Website: invivyd.com

Total Funding: $466.0M
Last Round: $336.0M Series CApr 2021
Rounds: 3
Type: Public

About

Invivyd is a clinical-stage biopharmaceutical company developing antibody-based medicines to protect against serious viral respiratory diseases. Using its proprietary INVYMAB platform, which combines viral surveillance, predictive modeling, and advanced antibody engineering, the company aims to create medicines more potent and resistant to viral evolution than the human immune system. Key programs target COVID-19, RSV, and measles.

Summary

Invivyd is a Biotech company based in Waltham, United States, founded in 2020. It has raised $466.0M in total across 3 rounds, most recently a $336.0M Series C round in Apr 2021. Investors include RA Capital Management, Polaris Partners and Mithril Capital.

LinkedIn X (Twitter)